Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05366816 · ClinicalTrials.gov registry record · Phase 2
ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST
A Phase 2 study of Gastrointestinal Stromal Tumors, sponsored by University of Miami.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT05366816 is a Phase 2 study of Gastrointestinal Stromal Tumors that is actively recruiting participants, run by University of Miami. The registered enrollment target is 48 participants, below the 90-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05366816, a Phase 2 study of Gastrointestinal Stromal Tumors, is actively recruiting participants, sponsored by University of Miami.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
Conditions Studied
Interventions
- DRUG Sunitinib
- DRUG Regorafenib
Study Locations (1)
Florida
- University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2023-10-17 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05366816
The ClinicalTrials.gov registry entry for NCT05366816 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 10 other Gastrointestinal Stromal Tumors trials with a reported enrollment target (47% lower). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastrointestinal Stromal Tumors appearing as the primary indexed condition, and to 2 interventions - of which Sunitinib is the first listed.
NCT05366816 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05366816 about?
NCT05366816 is a clinical study titled "ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST". The purpose of this research is to test if mutations (changes in DNA) in exons (segment of DNA or RNA containing information that has the instructions for making proteins) in the KIT gene can be used to predict the body's response to standard of care treatment.
What is the current status of trial NCT05366816?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2023-10-17. Estimated completion is 2028-12-31.
What conditions does trial NCT05366816 study?
This clinical trial studies the following conditions: Gastrointestinal Stromal Tumors.
What interventions are being tested in trial NCT05366816?
The interventions under investigation include: Sunitinib (DRUG), Regorafenib (DRUG).
Who is sponsoring clinical trial NCT05366816?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05366816 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastrointestinal Stromal Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Imatinib TDM in GIST
RECRUITING · Phase 2
-
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting.
ACTIVE NOT RECRUITING · Phase 2
-
Temozolomide (TMZ) in Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST)
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 2 Study of XL820 in Adults With Advanced GIST Resistant to Imatinib and/or Sunitinib
COMPLETED · Phase 2
-
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.